Why Analyst Sees Deep Value in Solar After Sell-Off
Credit Suisse has weighed in on the solar sector, and the firm believes the stocks can make solid gains in 2015.
Credit Suisse has weighed in on the solar sector, and the firm believes the stocks can make solid gains in 2015.
Credit Suisse upgraded Apple to Outperform and raised its target price on Tuesday. We also saw an increased outlook from Canaccord Genuity.
Recent short interest data show that investors seem to be growing marginally more optimistic on the semiconductor industry as a whole.
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Alcoa kicked off the earnings season and reported its fourth-quarter results Monday after the market close.
ThinkstockAlcatel-Lucent SA (NYSE: ALU) was downgraded by Merrill Lynch to Underperform from Neutral. This was effectively the opposite of what Credit Suisse had done in the previous week when it raised Alcatel-Lucnet to Outperform…
Merrill Lynch has upgraded Windstream Holdings and Frontier Communications to Buy ratings from Neutral.
Celgene Corp. provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare Conference.
Tekmira Pharmaceuticals and OnCore Biopharma have announced that they will merge to form a new company to develop a curative regimen for hepatitis B patients.
Lululemon Athletica has updated its guidance for its fourth quarter and the 2014 fiscal year in the wake of strong sales.
Tiffany reported lower-than-expected sales results for the two-month holiday period ended December 31, citing headwinds from a strong U.S. dollar.
SanDisk, the leader in flash memory, announced on Monday that it is lowering its revenue guidance for its fiscal fourth quarter.
Yelp has received an interesting upgrade from Merrill Lynch, which said the company as well positioned to capitalize on key Internet trends.
Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody discovery platform.
Bed Bath & Beyond reported mixed third-quarter results Thursday after the market close and analysts have already begun to weigh in.
Five Below announced increased sales from last year, but the total was less than previously guided. The retailer cited soft pre-Christmas sales.
Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
The U.S. Department of Labor has released the Unemployment Situation Report for the month of December. Overall, there was a solid pace in December.
Key considerations for the year ahead include how American Express will appeal to the market with mobile payments and whether it can expand its customer base.
ThinkstockBed Bath & Beyond Inc. (NASDAQ: BBBY) reported its third-quarter earnings Thursday after the market close as $1.23 in earnings per share and $2.94 billion in revenue, against Thomson Reuters consensus estimates of $1.19…